Here's the reply I got from Leo:
Hi
I cant comment on specific cohorts in an email. I must do so in a public communication to all shareholders. I can say we have not yet reached maximum tolerated dose and we are pleased with the trial. I expect to update all soon.
Best wishes,
Leo Ehrlich